亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Management of ETV6‐ABL1‐positive childhood acute lymphoblastic leukaemia: report of two cases, a literature review and a call for action

医学 淋巴细胞白血病 动作(物理) 急性淋巴细胞白血病 白血病 儿科 内科学 物理 量子力学
作者
Jiajia Zheng,Shuiyan Wu,Yixin Hu,Li Gao,Jing Ling,Qin Lu,Xuanxuan Shi,Peifang Xiao,Raul C. Ribeiro,Shaoyan Hu
出处
期刊:British Journal of Haematology [Wiley]
卷期号:193 (1): 197-200 被引量:3
标识
DOI:10.1111/bjh.17271
摘要

The 5-year overall survival (OS) of children with acute lymphoblastic leukaemia (ALL) has approached 90% by using risk-stratified chemotherapy intensive treatment protocols. The remaining 10% consists of ALL cases with rare genetic subtypes, which usually have primary resistance to standard chemotherapy regimens.1 Alternative treatment approaches are necessary for these rare subtypes of ALL. The ETS variant transcription factor 6-Abelson proto-oncogene 1, non-receptor tyrosine kinase [ETV6-ABL1, previously known as translocation-ETS-leukaemia-ABL (TEL-ABL)] was first observed in a child with B-cell precursor ALL (BCP-ALL),2 occurs in <0·2% of individuals aged <18 years, with only 16 cases in childhood ALL described.2-10 The ETV6-ABL1 rearrangement is complex, including at least three chromosomal breaks and the generation of two fusion products, both of which have elevated activity of tyrosine kinase (TK).10 Currently, ETV6-ABL1-positive ALL has been assigned to a heterogeneous high-risk subtype denominated Philadelphia chromosome (Ph)-like ALL. The management of Ph-like ALL has not been uniform.3 Similarly, the treatment approaches have not been consistent among children and adolescents with ETV6-ABL1-positive ALL, although there is strong evidence that haematopoietic neoplasms harbouring ETV6-ABL1 rearrangements are responsive to TK inhibitors (TKIs).11 In the present report, we describe the clinical and long-term outcomes of two children with ETV6-ABL1-positive ALL, review the literature and propose strategies to improve the management of this subtype of ALL. A previously healthy 7-year-old girl was admitted to our hospital with a 4-day history of fever. Laboratory evaluation demonstrated a white blood cell count (WBC) of 102.5 × 109/l, with 73% blasts on the differential. Bone marrow (BM) evaluation revealed a hypercellular marrow with 82% lymphoblasts by morphology. By flow cytometry, lymphoblasts expressed human leucocyte antigen-DR isotype (HLA-DR), CD123, CD19, CD10, CD20, CD58, CD79a and terminal deoxynucleotidyl transferase (TdT), and lacked T-cell expression myeloid and monocytic markers. Conventional cytogenetics analysis revealed a normal karyotype (46, XX). Fluorescence in situ hybridisation (FISH) analysis revealed negative results for breakpoint cluster region (BCR)-ABL1, histone-lysine N-methyltransferase 2A (KMT2A) and ETV6-Runt-related transcription factor 1 (RUNX1) rearrangements. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis showed ETV6-ABL1 fusion transcripts. The patient was treated according to the Chinese Children's Leukemia Group (CCLG)-ALL-2008 protocol12 and attained complete remission (CR) by morphological examination of the BM on day 33. Measurement of minimal residual disease (MRD) was negative by both flow cytometry and PCR analysis. ETV6-ABL1 fusion transcripts were not detected by PCR as well. The leukaemia relapse was noted 32 months after diagnosis, with a large pelvic mass and BM involvement. The features of the leukaemia cells at diagnosis and relapse were similar, including the ETV6-ABL1 transcripts. The patient was treated with dexamethasone, vincristine, mitoxantrone and L-asparaginase. Imatinib at a daily dose of 300 mg/m2 was started on the first day of salvage therapy. The therapeutic response was rapid and profound, as demonstrated by the absence of the ETV6-ABL1 transcripts on day 7 of induction. However, cells with a leukaemia phenotype were detected by flow cytometry at a level of 2·01 × 10−4. The patient underwent allogeneic hematopoietic stem cell transplantation (HSCT). The post-transplant course was uneventful. By flow cytometry, MRD has been negative (<1 × 10−4). Imatinib was started 28 days after the HSCT and maintained for 2 years. The patient has remained in second CR for >3 years after HSCT. A previously healthy 3-year-old boy was admitted to our hospital in October 2014. Initial laboratory evaluation revealed a WBC count of 15·8 × 109/l, with 29% blasts on the differential. BM analysis showed the normal cellularity replaced by lymphoblasts expressing HLA-DR, CD123, CD19, CD10, CD58, CD34, CD79a and TdT. Cytogenetic and FISH analyses were unremarkable (46, XY, lacking BCR-ABL1, KMT2A and ETV6-RUNX1 rearrangements). RT-PCR analysis showed ETV6-ABL1 fusion transcripts. The patient received treatment according to the CCLG-ALL-2008 treatment protocol12 and a TKI was not administered. BM analysis on remission induction day 15 of induction showed no evidence of blasts by morphology. Flow cytometric analysis revealed 5.0 × 10−3 cells with the leukaemia phenotype. On day 33, there was no evidence of disease by morphology or flow cytometry (sensitivity <1 × 10−4). ETV6-ABL1 transcripts were undetectable. To date, he has been in the first CR for >5 years. Our present study illustrates the heterogeneity of ETV6-ABL1-positive paediatric ALL. The degree of the response of our first patient, including negative PCR for the ETV6-ABL1 transcripts on day 7 of salvage therapy, was unexpected and suggests that ETV6-ABL1-positive ALL is sensitive to TKIs. The second patient treated successfully with conventional chemotherapy indicates that prognostic implications of this genetic abnormality may vary. Of interest, our second case had a good response to standard chemotherapy and treated as a low-risk ALL. The clinical and outcome features of previously reported paediatric cases with this genetic abnormality also corroborate the variability of clinical and biological features, including 13 with progenitor B-cell ALL and two with T-cell ALL (Table 1). In adults, ETV6-ABL1-positive leukaemias have included ALL, acute myeloid leukaemia, atypical chronic myeloid leukaemia, chronic eosinophilic leukaemia, myelodysplastic and myeloproliferative neoplasms. Therefore, the morphological and immunophenotype distribution pattern of ETV6-ABL1-positive cases resemble those of classic BCR-ABL1-positive leukaemias. The rarity of the former might be due in part to the complexity of the rearrangement, which requires at least three break-and-join events.13 46,XY,inv(1),t(1;9),t(1;9;12) del(1),t(9;12),t(1;9) CNS irradiation re-induction CHT 47,XXY,del(6), ins(9;12),inv(9) Given the marked clinical and biological similarities among BCR-ABL1- and ETV6-ABL1-positive leukaemias and the impossibility of predicting reliably those patients who could be cured with conventional chemotherapy alone, we propose that all paediatric ETV6-ABL1-positive cases be treated with a TKI starting in induction remission and continuing during the entire treatment. This strategy has now been considered the standard of care for children with BCR-ABL1-positive ALL.14 Furthermore, we suggest that ETV6-ABL1-positive leukaemia be classified as a Ph+ variant instead of a Ph-like ALL. Finally, we recommend ETV6-ABL1 genetic analysis be included in the testing panel of children with newly or relapsed ALL and call for international ALL groups to collaborate to determine the true incidence of ETV6-ABL1-positive leukaemias among children and adolescents, to refine the treatment approaches for patients with this subtype of ALL. Shaoyan Hu and Jiajia Zheng designed the study; Peifang Xiao, Li Gao, Jing Ling, Qin Lu and Xuanxuan Shi provided patient material and clinical data; Raul Ribeiro, Shaoyan Hu and Jiajia Zheng analysed data. Jiajia Zheng, Shuiyan Wu and Yixin Hu wrote the manuscript; Raul Ribeiro and Shaoyan Hu reviewed the results, commented on draft manuscripts and revised the manuscript; finally, all the authors critically reviewed the manuscript and gave their approval. The authors declare that they have no conflict of interest. This work was supported by the following grants: 2020ZKPB02, BE2017659, CXTDA2017014, SZZX201504, SZS201615, SS201809 and National Clinical Research Center for Hematological Disorders. Raul C. Ribeiro, MD, is partially funded by National Cancer Institute (NCI) grant CA21765 and by the American Lebanese and Syrian Associated Charities (ALSAC). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
天天快乐的应助被科研通管家采纳,获得10
刚刚
FashionBoy的应助被科研通管家采纳,获得10
刚刚
我是老大的应助被科研通管家采纳,获得10
刚刚
Nole的应助被科研通管家采纳,获得10
1秒前
万能图书馆的应助被的速度采纳,获得10
3秒前
学霸业的应助被ljxx采纳,获得10
5秒前
今后的应助被kiki采纳,获得10
6秒前
6秒前
Zhangyuexin1完成签到 ,获得积分10
8秒前
10秒前
学术小白发布了新的文献求助10
11秒前
IF完成签到,获得积分10
14秒前
djuanyx完成签到,获得积分10
16秒前
17秒前
李秋莉完成签到 ,获得积分10
19秒前
典雅的念梦完成签到,获得积分10
19秒前
mmyhn发布了新的文献求助10
22秒前
科研通AI65的应助被萧雨墨采纳,获得10
22秒前
27秒前
30秒前
31秒前
无花果的应助被suyongye采纳,获得10
31秒前
萧雨墨发布了新的文献求助10
32秒前
温暖山晴完成签到,获得积分10
35秒前
ket的应助被YUYUYU采纳,获得10
42秒前
zzmine完成签到 ,获得积分10
42秒前
定海神针铁完成签到,获得积分10
43秒前
萧雨墨发布了新的文献求助10
44秒前
大模型的应助被开朗天问采纳,获得10
45秒前
带派不老铁完成签到 ,获得积分10
46秒前
坚强血茗完成签到 ,获得积分10
51秒前
52秒前
55秒前
suyongye完成签到,获得积分10
56秒前
熊猫四海完成签到 ,获得积分10
1分钟前
科研通AI6.4的应助被YCLING采纳,获得10
1分钟前
玖嬴完成签到,获得积分10
1分钟前
Owen的应助被北极幸运星采纳,获得20
1分钟前
可靠之玉发布了新的文献求助30
1分钟前
helloWorld完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190049
求助须知:如何正确求助?哪些是违规求助? 9577165
关于积分的说明 21851842
捐赠科研通 7788131
什么是DOI,文献DOI怎么找? 3436227
关于科研通互助平台的介绍 2559910
邀请新用户注册赠送积分活动 2482768